A SINGLE pill has the potential to treat multiple brain conditions including Alzheimer's, Parkinson's and multiple sclerosis.
Scientists have developed a new class of drug that can be taken orally which prevents the damaging effects of inflammation in the brain.
Early results from animal studies suggest it could be effective against a plethora of devastating brain conditions.
They include Alzheimer's and Parkinson's disease, multiple sclerosis (MS), motor neurone disease, frontotemporal dementia, and complications from traumatic brain injury.
Two of the drugs, known as MW151 and MW189, have been patented by US scientists at Northwestern University in Chicago.
They work by blocking excess production of damaging immune system signalling molecules called pro-inflammatory cytokines.
Research published in the Journal of Neuroscience showed how early treatment with MW151 prevented the development of full-blown Alzheimer's in laboratory mice.
Scientists say the drugs offer a completely different approach to treating the disease to others currently being tested.
These target the accumulation of beta amyloid protein deposits in the brain which are a key feature of Alzheimer's. In contrast the new drugs are designed to stop inflammation disrupting wiring in the brain and killing neurons.
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article